7-OH is being banned: what to do if you use it

Current status at a glance (as of July 21, 2026)

Key Takeaways

• The ban has not taken effect yet, but the earliest it can is August 5, 2026. Once the order publishes, concentrated 7-OH tablets, gummies, and shots become Schedule I controlled substances under federal law.
• The action targets concentrated and synthetic products, not natural kratom leaf. The 0.05% threshold is designed to capture products made in labs, not the plant itself.
• The real risk for daily users is involuntary withdrawal on someone else's timeline. When products leave shelves, people who have been dosing daily face a hard stop with no preparation.
• Stockpiling is not the answer. It deepens dependence, raises overdose risk, and only postpones the same day.
• You have a window right now. Getting into treatment before supply disappears means the transition is planned and supervised rather than forced and chaotic.

What the DEA actually announced

On July 1, 2026, the Drug Enforcement Administration announced its intent to temporarily place concentrated 7-OH in Schedule I of the Controlled Substances Act. Two notices were filed and published in the Federal Register on July 6, 2026 (Docket DEA-1570 and related docket):

Notice 1: 7-OH above a specified threshold. Covers 7-hydroxymitragynine at more than 0.05% by dry weight in botanical material, or more than 0.05% by concentration or more than 1.00 milligram per article in synthetic or processed products. Virtually all commercial 7-OH tablets, gummies, and shots fall above this threshold.

Notice 2: Three synthetic derivatives. Covers mitragynine pseudoindoxyl (MP), MGM-15, and MGM-16 at any concentration. None of these compounds occur naturally in the kratom plant.

What is not covered: The DEA and HHS were explicit in their joint statement that this action does not target botanical kratom products containing naturally occurring 7-OH below the specified threshold. Natural leaf kratom is not the subject of this scheduling action.

Timeline:

• July 1, 2026: DEA files notices of intent
• July 6, 2026: Notices publish in Federal Register; HHS comment period opens
• July 31, 2026: HHS public comment period closes
• August 5, 2026 (earliest): Temporary scheduling order can take effect
• Up to 2 to 3 years: Duration of temporary scheduling while permanent rules are considered

The debate: Advocacy groups representing 7-OH product manufacturers have signaled legal challenges and objected to the use of emergency scheduling authority. The American Kratom Association, which represents botanical kratom consumers, supported the action because it draws a clear line between natural leaf and concentrated synthetic products. The leaf/extract distinction is the core of both the regulatory action and the disagreement around it.

Why concentrated 7-OH is so habit-forming

This is worth explaining because a lot of people who use it did not know what they were walking into.

The DEA's notice describes 7-OH as sharing a pharmacological profile with Schedule II opioids, with abuse potential, tolerance, dependence, and respiratory depression comparable to classical opioids. The FDA's 2025 scientific assessment documented this in detail.

What made it feel different from a drug was the delivery mechanism: sold at a gas station, labeled as a supplement, described with wellness language. The product was legal, available over the counter, and presented as botanical. That framing was marketing, not pharmacology.

Concentrated 7-OH activates mu-opioid receptors at potency levels far above what the natural kratom leaf produces. Unlike kratom leaf, which has a ceiling effect that limits respiratory depression, concentrated products have no protective ceiling. Dependence can form within days to weeks of regular use. Tolerance builds, doses escalate, and the window between "the amount that works" and "more than last week" closes faster than most people anticipate.

If this caught up to you without feeling like a conscious choice to develop an opioid habit, that is how the product is designed to work. It is not a personal failing.

What happens to people who relied on it when supply disappears

This is the part of the ban that does not get talked about enough: concentrated 7-OH withdrawal comes on fast. For most people, symptoms begin within 4 to 6 hours of the last dose. The peak arrives within 2 to 4 days and can be severe, with muscle aches, sweating, anxiety, insomnia, GI distress, and intense cravings.

When products leave shelves abruptly, people who have been dosing daily face that withdrawal on a timeline set by a Federal Register notice rather than a clinical plan. That is the scenario worth avoiding.

Two impulses that make it worse:

Stockpiling. It is the natural first thought. It does not help. Stockpiling deepens the dependence you will eventually have to address, raises overdose risk as product quality and batch potency continue to vary, and simply delays the same day by a few weeks. Planning treatment is the productive version of the same impulse.

Panic-quitting cold turkey. Stopping abruptly from significant 7-OH dependence produces full-intensity withdrawal, the hardest and most relapse-prone version of stopping. For most people with daily concentrated 7-OH use, unsupported cold turkey is poorly matched to the pharmacology. See Kratom Withdrawal Timeline for what that looks like.

Switching to kratom leaf. This feels like a step down, but it maintains the same opioid receptor dependence in a milder form. It is not a taper; it is a lateral move. The same withdrawal eventually arrives when the leaf is stopped. See Can You Switch from 7-OH Back to Kratom Powder? for the full explanation.

The ban is not the enemy. Being unprepared for it is.

What you can do in the next few weeks

The window between now and when the order takes effect is the most useful period to act. Here is why:

Starting treatment before supply runs out means:

• The transition is supervised, not forced
• Withdrawal symptoms are largely prevented rather than endured
• You are not making critical clinical decisions in the middle of acute withdrawal

What treatment looks like: Buprenorphine/naloxone (Suboxone) is the evidence-based treatment for 7-OH and kratom dependence. It works by stabilizing the same mu-opioid receptors that 7-OH activates, which is why it prevents withdrawal and cravings. A published 2026 clinical guidance paper in Annals of Internal Medicine recommends buprenorphine as the preferred treatment for 7-OH dependence.

How to access it: Telehealth buprenorphine is available in most U.S. states without an in-person visit, often the same day you reach out. You do not have to step away from work, disclose anything to your employer, or navigate a clinic. See Can You Get Suboxone for Kratom Addiction Online? for the current rules and what the process looks like.

If you are thinking "I only use 7-OH, I probably don't qualify": You do. People whose only substance is concentrated kratom or 7-OH are treated with buprenorphine. The pharmacology qualifies you; the clinical evaluation confirms it. See "I Only Use Kratom" — Why That Still Qualifies for MAT.

If you are not sure whether you need help: Ask yourself whether skipping your usual dose feels optional or genuinely difficult. If the answer is the latter, that is physical dependence, and treatment is what addresses it.

What to tell a clinician

When you reach out for a telehealth evaluation, honest information helps the provider make the right clinical plan:

• What product you have been using and roughly how much
• How long you have been using it
• When you last used
• Whether you have tried to stop before and what happened
• Any other medications or substances you use

That is all they need. The evaluation is a clinical conversation, not a test. See Bicycle Health's treatment page for how the process works.

Frequently Asked Questions

Is 7-OH already illegal?

As of July 21, 2026, no. The DEA published notices of intent on July 6, 2026, but the temporary scheduling order cannot take effect before August 5, 2026. Several states have their own bans already in effect (including Tennessee, Kansas, Florida, and others), and those state-level restrictions apply now. For state-by-state status and the full federal picture, see The 2026 7-OH Legal Landscape.

Will kratom leaf products be banned too?

No, under the federal action. The DEA and HHS were explicit that this action targets concentrated and synthetic 7-OH products above a specified threshold. Natural kratom leaf containing trace, naturally occurring 7-OH below 0.05% by dry weight is not covered. Some states ban all kratom including the leaf under their own laws, which is separate from the federal action.

What happens to 7-OH products currently on shelves?

Once the temporary Schedule I order takes effect, manufacturing, distribution, sale, and possession of covered products become subject to federal criminal, civil, and administrative penalties. Products would need to be pulled from shelves. Exactly how quickly this will happen and what enforcement looks like in practice will become clearer as the order's effective date approaches.

Can I just stockpile 7-OH before the ban?

This is understandable as an impulse but not a helpful plan. Stockpiling deepens physical dependence, raises overdose risk given variable product potency, and delays addressing the underlying issue. If you have been using 7-OH to the point where losing access to it is frightening, that is the situation treatment is designed to help with.

What if I am in withdrawal already?

If you are currently experiencing 7-OH withdrawal and need help today, contact a clinician or call SAMHSA's free helpline at 1-800-662-4357. Buprenorphine can be prescribed via telehealth in most states and can be started once moderate withdrawal has begun. See Get emergency access to buprenorphine.